Pfizer applies to Swissmedic for authorisation of another COVID-19 vaccine

People pose with syringe with needle in front of displayed Pfizer logo in this illustration taken, December 11, 2021. REUTERS/Dado Ruvic/Illustration

BERLIN, Sept 22 (Reuters) - Pfizer said on Thursday it had submitted an application to Swissmedic for authorisation of a further bivalent COVID-19 vaccine.

The ready-to-use dispersion for injection contained both messenger RNA (mRNA) from the original Pfizer/BioNTech COVID-19 vaccine and mRNA coding for the spike protein of Omicron variants BA.4 and BA.5, Pfizer said.

Register now for FREE unlimited access to
Reporting by Kirsti Knolle Editing by Paul Carrel

Our Standards: The Thomson Reuters Trust Principles.